Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. 1985

F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig

Protective immunity against malaria can be obtained by vaccination with irradiated sporozoites. The protective antigens known as circumsporozoite (CS) proteins, are polypeptides that cover the surface membrane of the parasite. The CS proteins contain species-specific immunodominant epitopes formed by tandem repeated sequences of amino acids. Here it is shown that the dominant epitope of Plasmodium falciparum is contained in the synthetic dodecapeptide Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Pro or (NANP)3. Monoclonal antibodies and most or all polyclonal human antibodies to the sporozoites react with (NANP)3, and polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present in CS proteins of P. falciparum from many parts of the world, this epitope is a logical target for vaccine development.

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine

Related Publications

F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
January 1986, Ciba Foundation symposium,
F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
September 1993, Deutsche medizinische Wochenschrift (1946),
F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
April 1991, Clinical and experimental immunology,
F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
January 2017, JCI insight,
F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
March 1988, Nature,
F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
January 1987, Nature,
F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
February 2006, Expert review of vaccines,
F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
January 1995, Lancet (London, England),
F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
January 2017, NPJ vaccines,
F Zavala, and J P Tam, and M R Hollingdale, and A H Cochrane, and I Quakyi, and R S Nussenzweig, and V Nussenzweig
March 2015, Trends in parasitology,
Copied contents to your clipboard!